Genetic sequencing for people with early gastric cancer or gastric adenoma
Official title: Clinical Sequencing Project for Early Gastric Cancer and Precancerous Gastric Adenoma Patients for Personalized Cancer Clinic
Run by Samsung Medical Center · NCT04665687 · Data updated 2026-11-12
This project will test whether genetic sequencing of tumor tissue, blood, and gastric fluids can find markers to diagnose early gastric cancer and predict recurrence in people with early gastric cancer or gastric adenoma.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 19 Years to 100 Years |
| Sex | All |
| Enrollment | 1730 (estimated) |
| Sponsor | Samsung Medical Center Academic / other |
| Locations | 1 site (Seoul) |
| Status | Recruiting |
| Started | December 17, 2020 |
| Main results expected | December 31, 2029 |
| Study ends | December 31, 2031 |
| Registry record updated | September 12, 2025 |
| Trial ID | NCT04665687 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥19 years) with histologically confirmed early gastric cancer or precancerous gastric adenoma who can provide tissue or blood samples and consent to follow-up are ideal candidates.
✕Probably not a fit
Patients who cannot provide sufficient tissue or blood samples, cannot attend the required follow-up visits, or have advanced disease or very limited life expectancy are unlikely to benefit from the study's findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational project collects tumor tissue and blood (and gastric juice when available) from adults with histologically confirmed early gastric cancer or gastric adenoma at baseline and after treatment (approximately 2 months, 1 year, and at recurrence). Extracted DNA from FFPE tumor samples and matched blood will be quality-checked (Nanodrop, Qubit) and subjected to targeted mutation profiling with the Ion AmpliSeq Cancer Panel V2 and copy-number analysis using a 21-gene nCounter CNV assay. The study aims to identify diagnostic markers for early disease and molecular signatures that predict metachronous recurrence after endoscopic resection. Results will be used to explore liquid biopsy approaches for less invasive detection and post-treatment surveillance.
Why it matters
Potential benefit: If successful, this work could produce blood- or gastric-fluid-based tests that detect early gastric cancer and predict recurrence, enabling less invasive treatment decisions and more personalized follow-up.
How similar studies have gone: Liquid biopsy and targeted sequencing have shown promising preliminary results in gastric and other cancers, but validated diagnostic or recurrence biomarkers for early gastric cancer have not yet been established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Those who are over the age of 19 2. Those who were histologically confirmed with early gastric cancer or precancerous gastric adenoma 3. Patients with early gastric cancer or precancerous gastric adenoma falling under the above criteria who have excess tissue stored from previous non-research purpose biopsy/endodoscopic removal for treatment and diagnosis 4. Those whose life expectancy is more than 3 months 5. Those who have voluntarily consented to participate in this clinical trial Exclusion Criteria: 1. Those who will not yield enough samples 2. Those who are considered inappropriate for this study in the discretion of the researchers
Where it's running
-
Samsung medical center
Seoul, South Korea Recruiting
Study contacts
- Principal investigator: Hyuk Lee, MD, PhD — Samsung Medical Center
- Study coordinator: Clinical Research Coordinator
- Email: hyejung1.cho@sbri.co.kr
- Phone: 82234106853
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
SPADE procedure for upper stomach cancer
A multicenter study will test the SPADE operation, a special stomach reconnection technique, in patients with early upper-stomach cancer undergoing proximal gastrectomy to see if it is safe and feasible.
-
LECS with sentinel node navigation for early gastric cancer
This study tests whether combining LECS with sentinel node navigation can treat early gastric cancer while preserving stomach function in eligible patients.
-
Image-guided platform helps find sentinel lymph nodes in early gastric cancer
This study tests whether an image-guided platform with a deep learning model can find and retrieve sentinel lymph nodes better than standard palpation in people with early gastric cancer undergoing LECS-SNNS.
-
Early Gastric Cancer in China: Real-World Outcomes by Treatment Type
This project will look at real-world outcomes for about 5,000 Chinese patients with early gastric cancer treated with endoscopic resection, laparoscopic surgery, open surgery, or a combined approach to see how treatments relate to survival and recurrence.
-
H. pylori status and tissue features to predict gastric cancer behavior after endoscopic treatment
This study tests whether current H. pylori infection status and tissue features can help predict how early gastric cancer will behave after endoscopic treatment.
-
Dual-endoscope Sentinel Lymph Node Navigation for Early Gastric Cancer
This study tests whether using two endoscopes to guide sentinel lymph node navigation during laparoscopic surgery is safe and effective for people with early gastric cancer who need additional surgery after initial endoscopic treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.